Federal Register / Vol. 77, No. 37 / Friday, February 24, 2012 / Notices 11137 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies should 

address one or more of the following 

points: (1) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the function of the agency, including 

whether the information will have 

practical utility; (2) Evaluate the 

accuracy of the agency’s estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Minimize the burden 

of the collection of information on those 

who are to respond, including the use 

of appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact Nathaniel 

Rothman, Senior Investigator for the 

Occupational and Environmental 

Epidemiology Branch, Division of 

Epidemiology and Genetics, National 

Cancer Institute, 6120 Executive 

Boulevard, Room 8118, Rockville, MD 

20892 or call non-toll-free number 301– 

496–9093 or email your request, 

including your address to: rothmann 

@mail.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60 days of the date of 

this publication. 

Dated: February 21, 2012. 

Vivian Horovitch-Kelley, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. 2012–4347 Filed 2–23–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Polyclonal Antibodies Useful for the 

Detection of Vangl1 and Vangl2 

Proteins Which Play a Role in 

Developmental Processes 

Description of Technology: Vangl1 

(Van Gogh like 1) and Vangl2 (Van Gogh 

like 2) are two core proteins mediating 

establishment of Planar Cell Polarity 

(PCP), which refers to the polarity of 

epithelial cells within a plane 

orthogonal to their apical-basal axis. 

Disruption of core PCP proteins leads to 

many developmental defects, including 

open neural tube, misorientation of 

sensory hair cells in the inner ear, 

polycystic kidney disease and skeletal 

deformations. In humans, mutations in 

Vangl1 and Vangl2 have been identified 

in patients with neural tube defects, 

such as spina bifida, the most common 

permanently disabling birth defect in 

the United States. NHGRI researchers 

have recently generated rabbit 

polyclonal antibodies against Vangl1 

and phosphorylated Vangl2 proteins 

that are suitable for endogenous Vangl1 

and Vangl2 detection. 

Potential Commercial Applications: 

Anti-Vangl1 and Vangl2 antibodies 

could be used in the development of 

diagnostic and therapeutic treatments 

for PCP-related developmental defects. 

Development Stage: 

• Pre-clinical. 

• In vitro data available. 

Inventors: Yingzi Yang and Bo Gao 

(NHGRI); Yingzi Yang and Hai Song 

(NHGRI). 

Publications: 

1. Gao B, et al. Wnt signaling 

gradients establish planar cell polarity 

by inducing Vangl2 phosphorylation 

through Ror2. Dev Cell. 2011 Feb 

15;20(2):163–176. [PMID 21316585] 

2. Song H, et al. Planar cell polarity 

breaks bilateral symmetry by controlling 

ciliary positioning. Nature. 2010 Jul 

15;466(7304):378–382. [PMID 20562861] 

Intellectual Property: HHS Reference 

Nos. E–135–2011/0 and E–136–2011/ 

0—Research Tools. Patent protection is 

not being pursued for these 

technologies. 

Licensing Contact: Suryanarayana 

(Sury) Vepa, Ph.D., J.D.; 301–435–5020; 

vepas@mail.nih.gov. 

Novel Biomarkers for Alcohol-Induced 

Liver Disease (ALD) 

Description of Technology: Alcoholinduced liver disease (ALD) is a leading 

cause of non accident-related deaths 

worldwide. ALD is reversible if 

identified in the early stages, but early 

diagnosis is difficult with existing tools. 

One problem associated with 

developing a new diagnostic tool is the 

genetic background associated 

heterogeneity in physiological responses 

to chronic alcohol consumption. The 

inventors of the present technology have 

solved this problem and have 

discovered background-independent 

novel biomarkers for ALD. In the 

current studies, the inventors generated 

two genetically distinct lines of 

PPARalpha-null mice and evaluated the 

levels of urine metabolites after alcohol 

exposure. The inventors have identified 

indole-3-lactic acid and phenyllactic 

acid as putative biomarkers for ALD. 

Indole-3-lactic acid and phenyllactic 

acid levels were significantly elevated 

in both lines of PPARalpha-null mice 

after two to three months of alcohol 

administration. The inventors had 

identified indole-3-lactic acid and 

phenyllactic acid to be background 

independent markers for ALD. 

Potential Commercial Applications: 

Useful for early non-invasive screening 

of ALD in large numbers of subjects 

irrespective of their genetic background. 

Competitive Advantages: 

• Easily adaptable for the 

development of highly sensitive 

spectroscopy-based assay kits. 

• Amenable for the development of 

high-throughput mass spectrometric 

analysis of urine samples to detect early 

onset of ALD. 

Development Stage: 

• Early-stage. 

• Pre-clinical. 

• In vivo data available (animal). 

Inventors: Soumen Kanti Manna and 

Frank J. Gonzalez (NCI). 

Publications: 

1. Manna SK, et al. UPLC–MS-based 

urine metabolomics reveals indole-3- 

lactic acid and phenyllactic acid as 

conserved biomarkers for alcoholinduced liver disease in the Ppara-null 

mouse model. J Proteome Res. 2011 Sep 

2;10(9):4120–4133. [PMID 21749142] 

2. Manna SK, et al. Identification of 

noninvasive biomarkers for alcoholinduced liver disease using urinary 

metabolomics and the Ppara-null 


srobinson on DSK4SPTVN1PROD with NOTICES
11138 Federal Register / Vol. 77, No. 37 / Friday, February 24, 2012 / Notices 

mouse. J Proteome Res. 2010 Aug 

6;9(8):4176–4188. [PMID 20540569] 

Intellectual Property: HHS Reference 

No. E–172–2011/0—U.S. Provisional 

Application No. 61/507,573 filed 13 Jul 

2011. 

Licensing Contact: Suryanarayana 

(Sury) Vepa, Ph.D., J.D.; 301–435–5020; 

vepas@mail.nih.gov. 

Biomarkers for Niemann-Pick Disease 

Type C and Related Disorders of 

Oxysterol Accumulation 

Description of Technology: NiemannPick disease type C (NPC) is a lethal 

lysosomal storage disorder characterized 

by liver disease and progressive 

neurodegeneration. Lysosomal storage is 

impaired by oxidized cholesterol 

(oxysterol) accumulation. Presenting 

signs and symptoms are nonspecific, 

and the diagnosis is frequently difficult 

and delayed. The inventors established 

a rapid ELISA assay to evaluate 

biomarker levels in serum. The ELISA 

assay tests a novel combination of two 

biomarkers significantly elevated in 

NPC patients, Cathepsin D and Galectin3. Other diseases can cause oxysterol 

accumulation, including other 

lysosomal storage diseases, cholesterol 

trafficking diseases, and 

neurodegenerative diseases. At least for 

the lysosomal storage diseases, the 

combination of elevated Cathepsin D 

and Galectin-3 appears specific for NPC. 

Cathepsin D is a lysosomal enzyme 

involved in protein degradation. The 

secreted Galectin-3 is mostly known as 

a chemoattractant for immune cells. 

Potential Commercial Applications: 

• NPC diagnosis. 

• NPC patient disease progression 

monitoring. 

• NPC therapeutic efficacy testing in 

Clinical Trials. 

• Application of above methods to 

related diseases. 

Competitive Advantages: 

• Fast and non-invasive ELISA serum 

assay. 

• Potential for high sensitivity. 

• Cost effective. 

Development Stage: 

• Pilot. 

• Early-stage. 

• In vivo data available (animal). 

• In vivo data available (human). 

Inventor: Forbes D. Porter (NICHD). 

Intellectual Property: HHS Reference 

No. E–302–2011/0—U.S. Provisional 

Application No. 61/576,062 filed 15 Dec 

2011. 

Licensing Contact: Betty B. Tong, 

Ph.D.; 301–594–6565; 

tongb@mail.nih.gov. 

Dated: February 21, 2012. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2012–4310 Filed 2–23–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Shared High 

End Instrumentation: NMR and X-ray. 

Date: March 13–14, 2012. 

Time: 7 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Kathryn M Koeller, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4166, 

MSC 7806, Bethesda, MD 20892, 301–435– 

2681, koellerk@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Hematology. 

Date: March 13–14, 2012. 

Time: 11:30 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Bukhtiar H Shah, DVM, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4120, 

MSC 7802, Bethesda, MD 20892, (301) 301 

806–7314, shahb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; P 41 

Competitive Revision. 

Date: March 14, 2012. 

Time: 11 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Khalid Masood, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5120, 

MSC 7854, Bethesda, MD 20892, 301–435– 

2392, masoodk@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Basic and Integrative 

Bioengineering. 

Date: March 21, 2012. 

Time: 11 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: General Services Administration 

(GSA), 301 7th Street SW., 1511, Washington, 

DC 20407. 

Contact Person: Ross D. Shonat, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6172, 

MSC 7892, Bethesda, MD 20892, 301–435– 

2786, ross.shonat@nih.hhs.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR10–225: 

Program Project: Center for Macromolecular 

Modeling and Bioinformatics. 

Date: March 21–23, 2012. 

Time: 7 p.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: University of Illinois at UrbanaChampaign, Urbana-Champaign, IL. 

Contact Person: Nitsa Rosenzweig, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1102, 

MSC 7760, Bethesda, MD 20892, (301) 435– 

1747, rosenzweign@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA Panel: 

Developmental System Biology. 

Date: March 22–23, 2012. 

Time: 8 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Raya Mandler, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5217, 

MSC 7840, Bethesda, MD 20892, 301–402– 

8228, rayam@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Basic and Integrative 

Bioengineering. 

Date: March 22, 2012. 

Time: 11 a.m. to 9 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: General Services Administration, 

Washington DC, 301 7th Street SW., 1511, 

Washington, DC 20407. 

Contact Person: David R Filpula, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6181, 

MSC 7892, Bethesda, MD 20892, 301–435– 

2902, filpuladr@mail.nih.gov. 


srobinson on DSK4SPTVN1PROD with NOTICES